Please use this identifier to cite or link to this item:
Clinical observation and management of COVID-19 patients
Taisheng Li
Hongzhou Lu
Wenhong Zhang
Novel Coronavirus
Acceso Abierto
Clinical management
Antiviral drugs
Three leading infectious disease experts in China were invited to share their bedside observations in the management ofCOVID-19 patients. Professor Taisheng Li was sent to Wuhan to provide frontline medical care. He depicts the clinicalcourse of SARS-CoV-2 infection. Furthermore, he observes the significant abnormality of coagulation function andproposes that the early intravenous immunoglobulin and low molecular weight heparin anticoagulation therapy arevery important. Professor Hongzhou Lu, a leader in China to try various anti-viral drugs, expresses concern on thequality of the ongoing clinical trials as most trials are small in scale and repetitive in nature, and emphasizes theimportance of the quick publication of clinical trial results. Regarding the traditional Chinese medicine, Professor Lusuggests to develop a creative evaluation system because of the complicated chemical compositions. ProfessorWenhong Zhang is responsible for Shanghai’s overall clinical management of the COVID-19 cases. He introduces theteam approach to manage COVID-19 patients. For severe or critically ill patients, in addition to the respiratorysupportive treatment, timely multiorgan evaluation and treatment is very crucial. The medical decisions andinterventions are carefully tailored to the unique characteristics of each patient.
Emerging Microbes & Infections
Epidemia COVID-19
Versión publicada
publishedVersion - Versión publicada
Appears in Collections:Artículos científicos

Upload archives